

PatientID: HIVDR-1715-23

Sebuttemba 27, 2023

## Color Code

■ HR: High-Level Resistance    ■ PLR: Potential Low-Level Resistance  
■ LR: Low-Level Resistance    ■ IR: Intermediate Resistance  
■ S: Susceptible

DRUG.CLASS	DRUG	RESISTANCE.PROFILE	DRMS.above.20.percent.prevalence
<b>PI</b>	ATV	<span style="background-color: green;">S</span>	
	DRV	<span style="background-color: green;">S</span>	
	FPV	<span style="background-color: green;">S</span>	
	IDV	<span style="background-color: green;">S</span>	
	LPV	<span style="background-color: green;">S</span>	
	NFV	<span style="background-color: green;">S</span>	
	SQV	<span style="background-color: green;">S</span>	
	TPV	<span style="background-color: green;">S</span>	
<b>NRTI</b>	ABC	<span style="background-color: orange;">LR</span>	M41ML;L210WL
	AZT	<span style="background-color: pink;">IR</span>	
	D4T	<span style="background-color: pink;">IR</span>	
	DDI	<span style="background-color: pink;">IR</span>	
	FTC	<span style="background-color: green;">S</span>	
	LMV	<span style="background-color: green;">S</span>	
	TDF	<span style="background-color: orange;">LR</span>	
<b>NNRTI</b>	DOR	<span style="background-color: pink;">IR</span>	E138EG;P225H;K103N
	EFV	<span style="background-color: red;">HR</span>	
	ETR	<span style="background-color: blue;">PLR</span>	
	NVP	<span style="background-color: red;">HR</span>	
	RPV	<span style="background-color: orange;">LR</span>	
<b>INSTI</b>	BIC	<span style="background-color: green;">S</span>	
	CAB	<span style="background-color: green;">S</span>	
	DTG	<span style="background-color: green;">S</span>	
	EVG	<span style="background-color: green;">S</span>	
	RAL	<span style="background-color: green;">S</span>	

## Appendix

### Drug abbreviations in full

DRUG.CLASS	ABBREVIATION	DRUG.NAME
<b>PI</b>	ATV	Atazanavir
	DRV	Darunavir
	FPV	Fosamprenavir
	IDV	Indinavir
	LPV	Lopinavir
	NFV	Nelfinavir
	SQV	Saquinavir
	TPV	Tipranavir
<b>NRTI</b>	ABC	Abacavir
	AZT	Azidothymidine
	DFT	Stavudine
	DDI	Didanosine
	FTC	Emtricitabine
	LMV	Lamivudine
	TDF	Tenofovir
<b>NNRTI</b>	DOR	Doravirine
	EFV	Efavirenz
	ETR	Etravirine
	NVP	Nevirapine
	RPV	Rilpivirine
<b>INSTI</b>	BIC	Bictegravir
	CAB	Cabotegravir
	DTG	Dolutegravir
	EVG	Elvitegravir
	RAL	Raltegravir

### Comments

DRUG.CLASS	COMMENTS
<b>PI</b>	
<b>NRTI</b>	L210W is a TAM that usually occurs in combination with M41L and T215Y. The combination of M41, L210W and T215Y causes high-level resistance to AZT and intermediate resistance to ABC and TDF.
	M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility.
<b>NNRTI</b>	E138Q/G are non-polymorphic accessory mutations selected by ETR occasionally NVP and EFV. They cause low-level reductions in susceptibility to NVP, RPV, and ETR.
	K103N is a non-polymorphic mutation that confers high-level reductions in NVP and EFV susceptibility. It is the most commonly transmitted DRM.
	P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.
<b>INSTI</b>	